Enlivex achieved positive results in a Phase 2 clinical trial of Allocerta Corona drug

Good news for Enlivex, which is traded on the stock exchange at a value of NIS 394 million. The company achieved positive intermediate results in a Phase 2 clinical trial in corona patients in a difficult and critical condition, which they treated using the drug Allocerta.
Of the eight corona patients who were recruited for the trial, six in critical condition and two in critical condition, seven fully recovered and were discharged from the hospital after less than five days on average from the date of treatment. The eighth patient who was recruited in a critical condition for drug treatment is experiencing clinical improvement and his condition is now classified as moderate-severe. This is the patient's sixth day of hospitalization after treatment, but the company is encouraging - as in the first trial it conducted a few weeks ago, it seems that treating patients in critical condition led to their discharge from the hospital on average after about nine days.
The patients who recovered join the 12 additional patients who participated in the first trial. They were released home healthy, after about five and a half days on average. The company did not report any serious side effects from the treatment, which was defined as "tolerable" by the company. "We started the drug Allocerta as a treatment for sepsis (SAA) - the third leading cause of death in the world - and not as a treatment for Covid-19 patients," Novik said.
In sepsis patients, similar to cobid-19 patients, the body experiences a systemic collapse and patients reach a critical and difficult condition. "Sepsis does not have any cure and its death rates are higher than the death rate in Covid-19," Novik explains, noting that in December the company is set to begin testing another 160 patients with Sepsis. "I am interested to know how the results of the trial in Cubid patients will affect the conclusions about the level of safety and drug outcomes in patients with sepsis, and what the trial means for the treatment of other diseases," he added.
The most prominent figures behind Annalebax (+ 29.49% 3500) are the founder, Prof. Dror Mevorach; The company's CEO, Oren Hershkovitz; and the chairman, Shai Novik, who owns 5.3% of its shares. The company has invested $ 60 million in the development of Allocerta.
Allocerta is used to treat autoimmune diseases, in which the immune system harms the body. An extreme reaction of the immune system can cause tissue damage and subsequent death. The extreme reaction leads to a storm of cytokines - proteins secreted by immune system cells. The drug Allocerta is given to patients through an infusion, and into it are put blood cells that have begun to die and have been taken from healthy people.
Because in the human immune system, central cells, called macrophages - responsible for the human body to lower or increase the immune system's response - began to rage in corona patients, society found a way to calm them down. She discovered that if cells that are going to be injected into the body, the macrophages 'swallow' those cells, relax and signal to the body that everything is fine and it is returning to equilibrium. The treatment is intended for people in a critical and difficult situation, whose problem is not the viral problem - but the fact that the immune system is raging.
"We do not know, there is a wall between the experiment and society. We get the information from the hospitals. I imagine that in the coming weeks we will receive from the researchers the ages of patients and other data that interests us, such as blood samples that show T cell parameters, and recovery rate. The fact that someone was discharged from the hospital after four days does not preclude the situation that he could have been discharged after two days in terms of parameters, but left him in the hospital for follow-up.
"What is most important to us now is that we do not see a change in patients' responses between the first and second treatment. They get up and release. Once we get the data, we will have to do blood tests, make sure there are no strong side effects - and see if there is potential to help more patients."
"Do not give placebo in life-saving trials. We try to test in the current trial that there are no side effects. We do the test compared to patients who receive standard treatment of antibiotics, steroids and other drugs. After we get all the results, go to the regulator and he will have to decide if he is interested in another trial. "Or these experiments provide it. Maybe, so that people do not die, it will give us a free marketing permit that can be treated."